Business
Precigen Provides Pipeline Updates at the 39th Annual J.P. Morgan Healthcare Conference
- Company announced its vision to transform the personalized cell therapy landscape using non-viral, antigen-specific UltraCAR-T® library approach - -
About this update from Precigen, Inc.
[{"type":"text","content":"- Company announced its vision to transform the personalized cell therapy landscape using non-viral, antigen-specific UltraCAR-T® library approach -\n - Preliminary data from Phase I study of PRGN-2009 AdenoVerse™ immunotherapy in HPV-associated cancers show increase in immune response upon repeated administration of PRGN-2009 monotherapy -\n - Preclinical data provided for new AdenoVerse immunotherapies in infectious disease -\n\n\nGERMANTOWN, Md., Jan. 13, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today presented clinical and preclinical updates at the 39th Annual J.P. Morgan Healthcare Conference. Helen Sabzevari, PhD, President and CEO of Precigen, presented a summary of 2020 clinical achievements and set forth Precigen's clinical goals for 2021. \n\n \n \n \n \n \n \n\n \nIn addition to reviewing the latest clinical updates for Precigen's PRGN-3005 UltraCAR-T, PRGN-3006 UltraCAR-T, AG019 ActoBiotics™, the presentation included the following additional announcements:\nUltraCAR-T Library Approach: Precigen introduced the Company's vision for a new UltraCAR-T library approach to transform the personalized cell therapy landscape for cancer patients. Precigen's goal is to develop and validate a library of non-viral plasmids to target tumor-associated antigens. Enabled by design and manufacturing advantages of UltraCAR-T, coupled with the capabilities of the UltraPorator™ system, Precigen is working to empower cancer centers to deliver personalized, autologous UltraCAR-T treatment with overnight manufacturing to any cancer patient. Based on the patient's cancer indication and biomarker profile, one or more non-viral plasmids would be selected from the library to build a personalized UltraCAR-T treatment. After initial treatment, this approach has the potential to allow for redosing of UltraCAR-T targeting the same or new tumor-associated antigen(s) based on the treatment response and the changes in antigen expression of the patient's tumor. Precigen believes that the combination of the advanced UltraVector® DNA construction platform and the ease of overnight manufacturing gives this library approach a proprietary advantage over traditional T-cell therapies. PRGN-2009 AdenoVerse Immunotherap...